50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to leverage an integrated and extensive genomics and transcriptomics discovery engine to identify antibodies targeted to newly discovered neoepitopes and to mobilize the human immune system of cancer patients to kill tumor cells and facilitate long-term remission.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-1585% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3167% match
“Our mission is to develop next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-11-2867% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2867% match
“Our mission is to develop next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.”In use 2018 – now·1 sighting·SEC Form S-1/A, filed 2018-05-0466% match
“Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-02-2566% match
“Our mission is to develop products and services based on leading genomics technologies that improve outcomes and enable improved effectiveness, productivity and safety in the research efforts of drug discovery and development companies worldwide.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1966% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2566% match
“Our mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche immune-compromised patient populations.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2466% match
“Our mission is to develop new and effective immune-oncologic therapeutics.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-10-1466% match
“Our mission is to offer an ecosystem of innovative discovery and translational research solutions that enable our customers to map the universe of biology and conduct scientific exploration that may lead to new therapies to improve the human condition.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-02-2866% match
“Our mission is to ‘democratize’ genetic analysis research with products that enable customers to detect and analyze complex genetic diseases by ultra-sensitive screening and monitoring of cell-free genomic targets.”In use 2015 – now·1 sighting·SEC Form S-1/A, filed 2015-03-3165% match
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1165% match
“Our mission is to accelerate the discovery, development and global access to targeted radioligand therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2765% match
“Our mission is to transform the field of proteomics by broadening access to high-quality proteomic data and to help support fundamental advancements across human health and medicine.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2665% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2465% match
“Our mission is to discover and develop effective biologic treatments applicable to a range of challenging, validated targets with high potential to help people with life-threatening conditions.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1965% match
“Our mission is to become the leader in the development of a new generation of DXL™ -modified monoclonal antibodies that have significantly improved therapeutic potency and novel properties over un-modified monoclonal antibodies.”In use 2007 – now·1 sighting·SEC Form 20-F, filed 2007-12-2665% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0465% match
“Our mission is to develop next generation cell and gene therapeutics with the capacity to cure.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0764% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0564% match
“Our mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1264% match
“Our mission is to discover and develop a pipeline of EPBs to treat a broad range of diseases and disorders, with an initial focus on cancers with a high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-04-2664% match
“Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-0164% match
“Our mission is to enable customers across the continuum of molecular research and clinical testing to unlock valuable insights faster, better and more efficiently - from the raw biological sample to the final interpreted results.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-1464% match
“Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0664% match
“Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-08-2864% match
“Our mission is to accelerate proteomics together.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-07-1664% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2664% match
“Our mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2464% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1464% match
“Our mission is to enable the promise of genomics to better human health.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2564% match
“Our mission is to transform the lives of patients living with devastating genetic diseases by building the leading integrated genetic medicine company focused on developing and commercializing potentially curative therapeutics based on our GeneRide platform.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-1564% match
“Our mission is to develop and commercialize innovative antibody-based therapeutics for the treatment of solid tumors that are designed to bind depending on the physical and chemical properties of tumors and their microenvironment.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-04-2964% match
“Our mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through our subsidiary MiNK Therapeutics, Inc. (“MiNK”)), and vaccine adjuvants (through our subsidiary SaponiQx, Inc. (“SaponiQx”)).”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1464% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1064% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2864% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1964% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1164% match
“Our mission is to bring off-the-shelf cellular immunotherapies with disease-transforming potential initially to patients with autoimmune diseases and cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2664% match
“Our mission is to enable anyone and any company to use our integrated open-access drug discovery and development platform to discover and develop new therapeutic products to benefit patients worldwide.”In use 2015 – now·1 sighting·SEC Form 20-F, filed 2015-04-1564% match
“Our mission is to apply the Versamune ® platform, our proprietary and versatile immunotherapy technology, to develop a new generation of immuno-oncology products that are effective and safe across a broad range of cancer types.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2763% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0963% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2663% match
“Our mission is to imagine and pioneer new ways to decode the biology of the proteome to improve human health.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0263% match
“Our mission is to power precision proteomics to enable the earliest detection of disease.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-04-1763% match
“Our mission is to translate our understanding of extracellular tRNA synthetase biology into novel first-in-class drug programs for conditions with unmet patient need.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-03-2063% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0163% match
“Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1063% match
“Our mission is to advance the understanding of fibrosis by building a biology-, chemistry- and screening- based engine to drive drug development across the spectrum of fibrotic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0163% match
Showing 1–50 of 50